The trial included 316 patients with stage I-IIA cervical cancer with at least ... and IB2 (34%) disease and squamous cell carcinoma histology (74%). Among the entire cohort, 92% of patients ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

M-Strip, the self-sampling kit for cervical cancer (HPV) and STI screening, provides a non-invasive alternative to ...

Almost all cases are caused by human papillomavirus (HPV) infection, with approximately 80% classified as squamous cell carcinoma (SCC); the remainder are largely adenocarcinomas. Cervical cancer ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...

A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.

The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

Iovance Biotherapeutics (NASDAQ: IOVA) just might be the right kind of biotech stock. The company has already achieved ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous ... cancer with a relatively low 5-year overall survival rate ...